Advertisement

Early and Late Treatment-Induced Toxicity

  • Wolfgang Dörr
  • Dorothea Riesenbeck
  • Carsten Nieder
Part of the Medical Radiology book series (MEDRAD)

Keywords

Radiat Oncol Biol Phys Oral Mucositis Keratinocyte Growth Factor Radiat Biol Normal Tissue Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreassen CN, Grau C, Lindegaard JC (2003) Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 13:62–72PubMedCrossRefGoogle Scholar
  2. Antonadou D, Pepelassi M, Synodinou M et al. (2002) Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739–747PubMedCrossRefGoogle Scholar
  3. Antonadou D, Throuvalas N, Petridis A et al (2003) Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 57:402–408PubMedCrossRefGoogle Scholar
  4. Athanassiou H, Antonadou D, Coliarakis N et al. (2003) Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 56:1154–1160PubMedCrossRefGoogle Scholar
  5. Badger C, Preston N, Seers K et al. (2004) Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev 18:CD003141Google Scholar
  6. Bairati I, Meyer F, Gelinas M et al. (2005) Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23:5805–5813PubMedCrossRefGoogle Scholar
  7. Baughan CA, Canney PA, Buchanan RB et al. (1993) A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol (R Coll Radiol) 5:19–24Google Scholar
  8. Belderbos J, Heemsbergen W, Hoogeman M et al. (2005) Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 75:157–164PubMedCrossRefGoogle Scholar
  9. Brizel DM, Wasserman TH, Henke M et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339–3345. Erratum in: J Clin Oncol 18:4110–4111PubMedGoogle Scholar
  10. Bourhis J. Crevoisier R de, Abdulkarim B et al. (2000) A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46:1105–1108PubMedCrossRefGoogle Scholar
  11. Bourhis J, Rosine D (2002) Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Semin Oncol 29(Suppl 19):61–62PubMedCrossRefGoogle Scholar
  12. Bourhis J, Thephamongkhol K, Pignon JP (2004) Randomized trials of amifostine and radiotherapy: Effect on survival? Semin Oncol 6Suppl 18:62–66CrossRefGoogle Scholar
  13. Breccia A, Badiello R, Trenta A et al. (1969) On the chemical radioprotection by organic selenium compounds in vivo. Radiat Res 38:483–492PubMedGoogle Scholar
  14. Bruns F, Micke O, Bremer M (2003) Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 1:121–130PubMedGoogle Scholar
  15. Bruns F, Buentzel J, Muecke R et al. (2004) Selenium in the treatment of head and neck lymphedema. Med Princ Pract 13:185–190PubMedCrossRefGoogle Scholar
  16. Buentzel J, Micke O, Adamietz IA et al. (2005) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys epubGoogle Scholar
  17. Burger A, Löffler H, Bamberg M et al. (1998) Molecular and cellular basis of radiation fibrosis. Int J Radiat Biol 73:401–408PubMedCrossRefGoogle Scholar
  18. Burtness B (2005) The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 5:1085–1093PubMedCrossRefGoogle Scholar
  19. Campbell BH, Spinelli K, Marbella AM et al. (2004) Aspiration, weight loss, and quality of life in head and neck cancer survivors. Arch Otolaryngol Head Neck Surg 130:1100–1103PubMedCrossRefGoogle Scholar
  20. Carpenter M, Epperly MW, Agarwal A et al. (2005) Inhalation delivery of manganese superoxide dismutase-plasmid/liposomes protects the murine lung from irradiation damage. Gene Ther 12:685–693PubMedCrossRefGoogle Scholar
  21. Cassatt DR, Fazenbaker CA, Kifle G et al. (2003a) Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Semin Oncol 30(Suppl) 18:31–39PubMedCrossRefGoogle Scholar
  22. Cassatt DR, Fazenbaker CA, Kifle G et al. (2003b) Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 57:794–802PubMedCrossRefGoogle Scholar
  23. Cassatt DR, Fazenbaker CA, Bachy CM et al. (2005) Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. Int J Radiat Oncol Biol Phys 61:901–907PubMedCrossRefGoogle Scholar
  24. Cheville AL, McGarvey CL, Petrek JA et al. (2003) Lymphedema management. Semin Radiat Oncol 13:290–301PubMedCrossRefGoogle Scholar
  25. Claude L, Perol D, Ginestet C et al. (2004) A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71:175–181PubMedCrossRefGoogle Scholar
  26. Coppes RP, Wierenga PK, Lombaert I et al. (2005) Mobilisation of bone marrow-derived stem cells reduces radiation-induced damage to salivary glands (Abstract). Molec Radiat Biol Oncol 6:100Google Scholar
  27. Cotrim AP, Sowers AL, Lodde BM et al. (2005) Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model. Clin Cancer Res 11:7564–7568PubMedCrossRefGoogle Scholar
  28. Delanian S, Porcher R, Rudant J et al. (2005) Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 23:8570–8579PubMedCrossRefGoogle Scholar
  29. Demark-Wahnefried W, Aziz NM, Rowland JH et al. (2005) Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 23:5814–5830PubMedCrossRefGoogle Scholar
  30. Dittmann K, Toulany M, Classen J et al. (2005) Selective radioprotection of normal tissues by Bowman-Birk proteinase inhibitor (BBI) in mice. Strahlenther Onkol 181:191–196PubMedCrossRefGoogle Scholar
  31. Dörr W (1997) Three A’s of repopulation during fractionated irradiation in squamous epithelia: Asymmetry loss, Acceleration of stem-cell divisions and Abortive divisions. Int J Radiat Biol 72:635–643PubMedCrossRefGoogle Scholar
  32. Dörr W (1998) Radiobiological models of normal tissue responses. Strahlenther Onkol 174(Suppl III):4–7PubMedGoogle Scholar
  33. Dörr W (2003a) Modulation of repopulation processes in oral mucosa: experimental results. Int J Radiat Biol 79:531–537PubMedCrossRefGoogle Scholar
  34. Dörr W (2003b) Oral mucosa: response modification by keratinocyte growth factor. In: Nieder C, Milas L, Ang KK (eds) Biological modification of radiation response. Springer, Berlin Heidelberg New York, pp 113–122Google Scholar
  35. Dörr W, Kummermehr J (1992) Increased radiation tolerance of mouse tongue epithelium after local conditioning. Int J Radiat Biol 61:369–379PubMedGoogle Scholar
  36. Dörr W, Hendry JH (2001) Consequential late effects in normal tissues. Radiother Oncol 61:223–231PubMedCrossRefGoogle Scholar
  37. Dörr W, Herrmann T (2003) Pathogenetic mechanisms of lung fibrosis. In: Nieder C, Milas L, Ang KK (eds) Biological modification of radiation response. Springer, Berlin Heidelberg New York, pp 29–36Google Scholar
  38. Dörr W, Gehrisch A (2005) Modification of oral mucositis by local or systemic administration of selenium: experimental studies in mice (Abstract). Supp Care Cancer 13:442Google Scholar
  39. Dörr W, Jakubec A, Kummermehr J et al. (1995) Effects of stimulated repopulation on oral mucositis during conventional radiotherapy. Radiother Oncol 37:100–107PubMedCrossRefGoogle Scholar
  40. Dörr W, Eckhardt M, Ehme A et al. (1998) Pathogenesis of the acute radiation response of the urinary bladder: experimental results. Strahlenther Onkol 174(Suppl III):93–95PubMedGoogle Scholar
  41. Dörr W, Krumsdorf D, Noack R (2000) Amelioration of late radiation effects in mouse urinary bladder by modulation of acute symptoms: experimental evidence for consequential late effects. Radiother Oncol 57(Suppl 1):S37–S39Google Scholar
  42. Dörr W, Noack R, Spekl K et al. (2001) Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol 77:341–347PubMedCrossRefGoogle Scholar
  43. Dörr W, Spekl K, Farrell CL (2002) Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 54:245–251PubMedCrossRefGoogle Scholar
  44. Dörr W, Reichel S, Spekl K (2005a) Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol 75:99–105PubMedCrossRefGoogle Scholar
  45. Dörr W, Bässler S, Reichel S et al. (2005b) Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (KGF): experimental studies in mice. Int J Radiat Oncol Biol Phys 62:881–88PubMedCrossRefGoogle Scholar
  46. Dörr W, Gabriel P, Siegemund A et al. (2005c) Modification of oral mucositis (mouse) by treatment with adult stem cells (Abstract). Supp Care Cancer 13:441Google Scholar
  47. Dörr W, Gabriel P, Siegemund A et al. (2005d) Modification of radiation effects in oral mucosa (mouse) by adult stem cells (Abstract). Molec Radiat Biol Oncol 6:91Google Scholar
  48. Dörr W, Heider K, Spekl K (2005e) Reduction of oral mucositis by palifermin (rHuKGF): dose effect of rHuKGF. Int J Radiat Biol 81:557–565PubMedCrossRefGoogle Scholar
  49. Duke RL, Campbell BH, Indresano AT et al. (2005) Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope 115:678–683PubMedGoogle Scholar
  50. El-Sayed S, Nabid A, Shelley W et al. (2002) Prophylaxis of radiation-induced mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 20:3956–3963PubMedCrossRefGoogle Scholar
  51. Epperly MW, Carpenter M, Agarwal A et al. (2004) Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis. In Vivo 18:401–410PubMedGoogle Scholar
  52. Ertekin MV, Koc M, Karslioglu I et al. (2004) Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys 58:167–174PubMedCrossRefGoogle Scholar
  53. Fajardo LF, Berthrong M, Anderson RE (2001) Radiation pathology. Oxford University Press, Oxford, pp 337–346Google Scholar
  54. Fehrmann A, Dörr W (2005) Effect of EGFR-inhibition on the radiation response of oral mucosa: experimental studies in mouse tongue epithelium. Int J Radiat Biol 81:437–443PubMedGoogle Scholar
  55. Ferreira PR, Fleck JF, Diehl A et al. (2004) Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 26:313–321PubMedCrossRefGoogle Scholar
  56. Food and Drug Administration (FDA) (2004) Palifermin (keratinocyte growth factor). www.fda.gov/cder/drug/infopage/palifermin/default.htm. Status 15.12.2004Google Scholar
  57. Ganser A, Karthaus M (1996) Clinical use of hematopoietic growth factors. Curr Opin Oncol 8:265–269PubMedCrossRefGoogle Scholar
  58. Ginsberg JP, Womer RB (2005) Preventing organ-specific chemotherapy toxicity. Eur J Cancer 41:2690–2700PubMedCrossRefGoogle Scholar
  59. Gottlober P, Steinert M, Bahren W et al. (2001) Interferon-gamma in 5 patients with cutaneous radiation syndrome after radiation therapy. Int J Radiat Oncol Biol Phys 50:159–166PubMedCrossRefGoogle Scholar
  60. Graham MV, Purdy JA, Emami B et al. (1999) Clinical dosevolume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45:323–329PubMedCrossRefGoogle Scholar
  61. Grdina DJ, Murley JS, Kataoka Y (2002) Radioprotectants: current status and new directions. Oncology 63(Suppl 2):2–10PubMedCrossRefGoogle Scholar
  62. Haddad R, Wirth L, Costello R et al. (2003) Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol 30(Suppl 18):84–88PubMedCrossRefGoogle Scholar
  63. Hakenjos L, Bamberg M, Rodemann HP (2000) TGFß mediated alterations of rat lung fibroblast differentiation resulting in the radiation-induced fibrotic phenotype. Int J Radiat Biol 76:503–509PubMedCrossRefGoogle Scholar
  64. Heflin LH, Meyerowitz BE, Hall P et al. (2005) Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 97:854–856PubMedCrossRefGoogle Scholar
  65. Hegazy MA, Fowler JF (1973) Cell population kinetics and desquamation reactions in plucked and unplucked mouse skin. II. Irradiated skin. Cell Tissue Kinet 6:587–602PubMedGoogle Scholar
  66. Hernando ML, Marks LB, Bentel GC et al. (2001) Radiationinduced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650–659PubMedCrossRefGoogle Scholar
  67. Hille A, Christiansen H, Pradier O et al. (2005) Effect of pentoxifylline and tocopherol on radiation proctitis/enteritis. Strahlenther Onkol 181:606–614PubMedCrossRefGoogle Scholar
  68. Holthusen H (1936) Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlung und deren Nutzanwendung zur Verhütung von Schäden (German). Strahlenther Onkol 57:30–36Google Scholar
  69. Hombrink J, Frohlich D, Glatzel M et al. (2000) Prevention of radiation-induced diarrhea by smectite. Results of a double-blind randomized, placebo-controlled multicenter study (German). Strahlenther Onkol 176:173–179PubMedCrossRefGoogle Scholar
  70. Hopewell JW (1997) The volume effect in radiotherapy: its biological significance. Br J Radiol 70:S32–S40PubMedGoogle Scholar
  71. Hopewell JW, Trott KR (2000) Volume effects in radiobiology as applied to radiotherapy. Radiother Oncol 56:283–288PubMedCrossRefGoogle Scholar
  72. Hopewell JW, Calvo W, Jaenke R et al. (1993) Microvasculature and radiation damage. Recent Results Cancer Res 130:1–16PubMedGoogle Scholar
  73. Hopewell JW, Nyman J, Turesson I (2003) Time factor for acute tissue reactions following fractionated irradiation: a balance between repopulation and enhanced radiosensitivity. Int J Radiat Biol 79:513–524PubMedCrossRefGoogle Scholar
  74. Joiner MC, Bentzen SM (2002) Time-dose relationships: the linear-quadratic approach. In: Steel GG (ed) Basic clinical radiobiology, 3rd edn. Arnold, London, pp 120–133Google Scholar
  75. Kase M (2001) Immunohistochemical studies on the expression of EGF and EGFR in irradiated mouse oral mucosa treated with KGF. Project Report, MSc Radiobiology Course, University College of LondonGoogle Scholar
  76. Kash KM, Mago R, Kunkel EJ (2005) Psychosocial oncology: supportive care for the cancer patient. Semin Oncol 32:211–218PubMedCrossRefGoogle Scholar
  77. Kilic D, Egehan I, Ozenirler S et al. (2000) Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. Radiother Oncol 57:125–129PubMedCrossRefGoogle Scholar
  78. Kilic D, Ozenirler S, Egehan I et al. (2001) Sulfasalazine decreases acute gastrointestinal complications due to pelvic radiotherapy. Ann Pharmacother 35:806–810PubMedCrossRefGoogle Scholar
  79. Kim TH, Cho KH, Pyo HR et al. (2005) Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 62:995–1002PubMedCrossRefGoogle Scholar
  80. Kirwan JM, Symonds P, Green JA et al. (2003) A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 68:217–226PubMedCrossRefGoogle Scholar
  81. Komaki R, Lee JS, Milas L et al. (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369–1377PubMedCrossRefGoogle Scholar
  82. Kozelsky TF, Meyers GE, Sloan JA et al. (2003) Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 21:1669–1674PubMedCrossRefGoogle Scholar
  83. Lee HK, Vaporciyan AA, Cox JD et al. (2003) Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57:1317–1322PubMedCrossRefGoogle Scholar
  84. Lindegaard JC, Grau C (2000) Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 57:113–118PubMedCrossRefGoogle Scholar
  85. Lord BI (2001) Radiation and haematopoietic growth factors. In: Dörr W (ed) Growth factors in the pathogenesis of radiation effects in normal tissues. Urban and Vogel, Munich, pp 17–24Google Scholar
  86. Maciejewski B, Zajusz A, Pilecki B et al. (1991) Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer. Radiother Oncol 22:7–11PubMedCrossRefGoogle Scholar
  87. Maduro JH, Pras E, Willemse PH et al. (2003) Acute and longterm toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29:471–488PubMedCrossRefGoogle Scholar
  88. Maranzano E, Feyer P, Molassiotis A et al. (2005) Evidencebased recommendations for the use of antiemetics in radiotherapy. Radiother Oncol 76:227–233PubMedCrossRefGoogle Scholar
  89. Martenson JA, Bollinger JW, Sloan JA et al. (2000) Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 18:1239–1245PubMedGoogle Scholar
  90. Martin T, Uhder K, Kurek R et al. (2002) Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial. Radiother Oncol 65:17–22PubMedCrossRefGoogle Scholar
  91. Masucci G, Broman P, Kelly C et al. (2005) Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Med Oncol 22:247–256PubMedCrossRefGoogle Scholar
  92. Michalowski A (1981) Effects of radiation on normal tissues: hypothetical mechanisms and limitations of in situ assays of clonogenicity. Radiat Environ Biophys 19:157–172PubMedCrossRefGoogle Scholar
  93. Nieder C, Price RE, Rivera B et al. (2002) Experimental data for administration of insulin-like growth factor 1 (IGF-1) and basic fibroblast growth factor (bFGF) for prevention of radiation myelopathy (German). Strahlenther Onkol 178:147–152PubMedCrossRefGoogle Scholar
  94. Nieder C, Andratschke NH, Wiedenmann N et al. (2004) Prevention of radiation-induced central nervous system toxicity: A role for amifostine? Anticancer Res 24:3803–3809PubMedGoogle Scholar
  95. Nieder C, Price RE, Rivera B et al. (2005a) Effects of insulinlike growth factor-1 (IGF-1) and amifostine in spinal cord reirradiation. Strahlenther Onkol 181:691–695PubMedCrossRefGoogle Scholar
  96. Nieder C, Zimmermann FB, Adam M et al. (2005b) The role of pentoxifylline as a modifier of radiation therapy. Cancer Treat Rev 31:448–455PubMedCrossRefGoogle Scholar
  97. Nishimura Y (2004) Rationale for chemoradiotherapy. Int J Clin Oncol 9:414–420PubMedCrossRefGoogle Scholar
  98. Parvez T, Almazaini A, Al Bouq Y et al. (2005) Scope of growth factor in cancer patients. J Coll Phys Surg Pak 15:375–377Google Scholar
  99. Patel AB, Edelman MJ, Kwok Y et al. (2004) Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfraction ated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60:1106–1112PubMedCrossRefGoogle Scholar
  100. Prosnitz RG, Chen YH, Marks LB (2005) Cardiac toxicity following thoracic radiation. Semin Oncol 32:S71–S80PubMedCrossRefGoogle Scholar
  101. Ravasco P, Monteiro-Grillo I, Vidal PM et al. (2005) Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 23:1431–1438PubMedCrossRefGoogle Scholar
  102. Resbeut M, Marteau P, Cowen D et al. (1997) A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol 44:59–63PubMedCrossRefGoogle Scholar
  103. Rodemann HP (2003) Role of radiation-induced signalling proteins in the response of vascular and connective tissues. In: Nieder C, Milas L, Ang KK (eds) Biological modification of radiation response. Springer, Berlin Heidelberg New York, pp 15–28Google Scholar
  104. Rodemann HP, Bamberg M (1995) Cellular basis of radiationinduced fibrosis. Radiother Oncol 35:83–90PubMedCrossRefGoogle Scholar
  105. Rubenstein EB, Peterson DE, Schubert M et al. (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046PubMedCrossRefGoogle Scholar
  106. Saarilahti K, Kajanti M, Joensuu T et al. (2002) Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiationinduced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys 54:479–485PubMedCrossRefGoogle Scholar
  107. Sagowski C, Wenzel S, Jenicke L et al. (2005) Sodium selenite is a potent radioptotector of the salivary glands of the rat: acute effects on the morphology and parenchymal function during fractionated irradiation. Eur Arch Otorhinolaryngol 262:459–464PubMedCrossRefGoogle Scholar
  108. Sonis ST, Elting LS, Keefe D et al. (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025PubMedCrossRefGoogle Scholar
  109. Spielberger R, Stiff P, Bensinger W et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 35:2590–2598CrossRefGoogle Scholar
  110. Staar S, Rudat V, Stützer H et al. (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicenter randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 50:1161–1171PubMedCrossRefGoogle Scholar
  111. Stellamans K, Lievens Y, Lambin P et al. (2002) Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial. Radiother Oncol 65:105–108PubMedCrossRefGoogle Scholar
  112. Stewart FA, van der Kogel A (2002) Proliferative and cellular organisation of normal tissues. In: Steel GG (ed) Basic clinical radiobiology, 3rd edn. Arnold, London, pp 23–29Google Scholar
  113. Stokman MA, Spijkervet FK, Burlage FR et al. (2003) Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a doubleblind randomised clinical trial. Br J Cancer 88:1012–1016PubMedCrossRefGoogle Scholar
  114. Su CK, Mehta V, Ravikumar L et al. (2004) Phase II doubleblind randomized study comparing oral aloe vera versus placebo to prevent radiation-induced mucositis in patients with head-and-neck neoplasms. Int J Radiat Oncol Biol Phys 60:171–177PubMedCrossRefGoogle Scholar
  115. Suntharalingam M, Jaboin J, Taylor R et al. (2004) The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 31(Suppl 18):2–7PubMedCrossRefGoogle Scholar
  116. Takeda K, Nemoto K, Saito H et al. (2005) Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. 2: Int J Radiat Oncol Biol Phys 62:626–629PubMedCrossRefGoogle Scholar
  117. Tannock IF (1996) Treatment of cancer with radiation and drugs. J Clin Oncol 14:3156–3174PubMedGoogle Scholar
  118. Thames HD, Hendry JH (1987) Fractionation in radiotherapy. Taylor and Francis, LondonGoogle Scholar
  119. Thames HD, Withers HR, Peters LJ et al. (1982) Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8:219–226PubMedGoogle Scholar
  120. Thorstad WL, Chao KS, Haughey B (2004) Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol 31(Suppl 18):8–12PubMedCrossRefGoogle Scholar
  121. Trotti A, Garden A, Warde P et al. (2004) A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58:674–681PubMedCrossRefGoogle Scholar
  122. Tsujino K, Hirota S, Endo M et al. (2003) Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55:110–115PubMedCrossRefGoogle Scholar
  123. Wang J, Zheng H, Sung CC et al. (1999) The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys 45:1289–1296PubMedCrossRefGoogle Scholar
  124. Wang J, Zheng H, Hauer-Jensen M (2001) Influence of shortterm octreotide administration on chronic tissue injury, transforming growth factor beta (TGF-beta) overexpression, and collagen accumulation in irradiated rat intestine. J Pharmacol Exp Ther 297:35–42PubMedGoogle Scholar
  125. Wasserman TH, Brizel DM, Henke M et al. (2005) Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985–990PubMedCrossRefGoogle Scholar
  126. Weiss JF, Srinivasan V, Kumar KS et al. (1992) Radioprotection by metals: selenium. Adv Space Res 12:223–231PubMedCrossRefGoogle Scholar
  127. Welzel G, Steinvorth S, Wenz F (2005) Cognitive effects of chemotherapy and/or cranial irradiation in adults. Strahlenther Onkol 181:141–156PubMedCrossRefGoogle Scholar
  128. Werner-Wasik M, Langer C, Movsas B (2005) Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. Semin Oncol 32(Suppl 3):S105–S108PubMedCrossRefGoogle Scholar
  129. Wheldon TE, Michalowski AS, Kirk J (1982) The effect of irradiation on function in self-renewing normal tissues with differing proliferative organisation. Br J Radiol 55:759–766PubMedCrossRefGoogle Scholar
  130. Willner J, Jost A, Baier K et al. (2003) A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 179:548–556PubMedCrossRefGoogle Scholar
  131. Zimmermann FB, Geinitz H, Schill S et al. (2005) Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 48:107–114PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Wolfgang Dörr
    • 1
  • Dorothea Riesenbeck
    • 2
  • Carsten Nieder
    • 3
  1. 1.Medical Faculty Carl Gustav CarusUniversity of Technology DresdenDresdenGermany
  2. 2.Klinik für Strahlentherapie und Radioonkologie, Marienhospital HerneRuhr-Universität BochumHerneGermany
  3. 3.Department of Radiation OncologyKlinikum rechts der Isar der Technischen Universität MünchenMünchenGermany

Personalised recommendations